Payment overview · 2025
General Payments
$591.66
30 reported records · 11 companies
Healthcare provider profile · identity verified
Kyle Magee Bennett, D.O.
Allopathic & Osteopathic Physicians|Hospitalist · GREENVILLE, SC · NPI 1740623115
Verified facts
What the public records show
CMS Open Payments records show Kyle Magee Bennett, D.O. received $591.66 in general payments during 2025 across 30 reported records.
Lilly USA, LLC accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $205.56 | 34.7% | 12 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $67.46 | 11.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.24 | 9.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.34 | 8.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.48 | 8.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.24 | 7.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.31 | 5.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.27 | 4.8% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $25.07 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.41 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $591.66 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.17 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.14 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $67.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $65.76 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.24 | 4 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $49.48 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 52 |
| Omeprazole | Omeprazole | 131 | 42 |
| Gabapentin | Gabapentin | 130 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 53 |
| Losartan Potassium | Losartan Potassium | 121 | 48 |
| Lisinopril | Lisinopril | 118 | 44 |
| Clonazepam | Clonazepam | 115 | 17 |
| Lorazepam | Lorazepam | 115 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 37 |
| Alprazolam | Alprazolam | 97 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 28 |
| Trazodone Hcl | Trazodone Hcl | 90 | 32 |
| Eliquis | Apixaban | 88 | 23 |
| Furosemide | Furosemide | 86 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 30 |
| Metformin Hcl | Metformin Hcl | 78 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 40 |
| Famotidine | Famotidine | 67 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 24 |
| Prednisone | Prednisone | 61 | 50 |
| Montelukast Sodium | Montelukast Sodium | 58 | 20 |
| Sertraline Hcl | Sertraline Hcl | 57 | 22 |
| Carvedilol | Carvedilol | 56 | 20 |
| Valsartan | Valsartan | 55 | 18 |
| Metformin Hcl Er | Metformin Hcl | 52 | 22 |
| Ondansetron Odt | Ondansetron | 47 | 19 |
| Spironolactone | Spironolactone | 46 | 18 |
| Glipizide Er | Glipizide | 45 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 16 |
| Ozempic | Semaglutide | 44 | 15 |
| Temazepam | Temazepam | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 15 |
| Meloxicam | Meloxicam | 38 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Mounjaro | Tirzepatide | 37 | 11 |
| Promethazine Hcl | Promethazine Hcl | 36 | 13 |
| Pregabalin | Pregabalin | 35 | 16 |
| Tramadol Hcl | Tramadol Hcl | 35 | 16 |
| Allopurinol | Allopurinol | 33 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 14 |
| Glipizide | Glipizide | 31 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 15 |
| Buspirone Hcl | Buspirone Hcl | 29 | 15 |
| Diazepam | Diazepam | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Methylprednisolone | Methylprednisolone | 28 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Naproxen | Naproxen | 22 | 13 |
| Nystatin | Nystatin | 22 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Finasteride | Finasteride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $591.66 · 30 records | Lilly USA, LLC | Dexcom G6 Transmitter, ELIQUIS, INSPIRE, JARDIANCE, KISUNLA, LAGEVRIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Tresiba, Veozah, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error